ID   YES_HUMAN               Reviewed;         543 AA.
AC   P07947; A6NLB3; D3DUH1;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   12-OCT-2022, entry version 242.
DE   RecName: Full=Tyrosine-protein kinase Yes;
DE            EC=2.7.10.2;
DE   AltName: Full=Proto-oncogene c-Yes;
DE   AltName: Full=p61-Yes;
GN   Name=YES1; Synonyms=YES;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2436037; DOI=10.1128/mcb.7.1.41-47.1987;
RA   Sukegawa J., Semba K., Yamanashi Y., Nishizawa M., Miyajima N.,
RA   Yamamoto T., Toyoshima K.;
RT   "Characterization of cDNA clones for the human c-yes gene.";
RL   Mol. Cell. Biol. 7:41-47(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D.,
RA   Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J.,
RA   Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L.,
RA   Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A.,
RA   Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C.,
RA   Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=2021534; DOI=10.1038/bjc.1991.121;
RA   Sugawara K., Sugawara I., Sukegawa J., Akatsuka T., Yamamoto T., Morita M.,
RA   Mori S., Toyoshima K.;
RT   "Distribution of c-yes-1 gene product in various cells and tissues.";
RL   Br. J. Cancer 63:508-513(1991).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=2067846;
RA   Krueger J., Zhao Y.H., Murphy D., Sudol M.;
RT   "Differential expression of p62c-yes in normal, hyperplastic and neoplastic
RT   human epidermis.";
RL   Oncogene 6:933-940(1991).
RN   [7]
RP   PALMITOYLATION.
RX   PubMed=7980442; DOI=10.1042/bj3030749;
RA   Koegl M., Zlatkine P., Ley S.C., Courtneidge S.A., Magee A.I.;
RT   "Palmitoylation of multiple Src-family kinases at a homologous N-terminal
RT   motif.";
RL   Biochem. J. 303:749-753(1994).
RN   [8]
RP   PHOSPHORYLATION BY CSK.
RX   PubMed=9281320; DOI=10.1006/abbi.1997.0236;
RA   Sun G., Budde R.J.;
RT   "Expression, purification, and initial characterization of human Yes
RT   protein tyrosine kinase from a bacterial expression system.";
RL   Arch. Biochem. Biophys. 345:135-142(1997).
RN   [9]
RP   PHOSPHORYLATION AT TYR-426, AND MUTAGENESIS OF TYR-426.
RX   PubMed=9794236; DOI=10.1038/sj.onc.1202076;
RA   Sun G., Sharma A.K., Budde R.J.;
RT   "Autophosphorylation of Src and Yes blocks their inactivation by Csk
RT   phosphorylation.";
RL   Oncogene 17:1587-1595(1998).
RN   [10]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=11901164; DOI=10.1083/jcb.200109005;
RA   Lee S.W., Bonnah R.A., Higashi D.L., Atkinson J.P., Milgram S.L., So M.;
RT   "CD46 is phosphorylated at tyrosine 354 upon infection of epithelial cells
RT   by Neisseria gonorrhoeae.";
RL   J. Cell Biol. 156:951-957(2002).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=16338789; DOI=10.1080/08977190500199360;
RA   Clump D.A., Qazi I.H., Sudol M., Flynn D.C.;
RT   "c-Yes response to growth factor activation.";
RL   Growth Factors 23:263-272(2005).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF CDK4.
RX   PubMed=18479465; DOI=10.1111/j.1742-4658.2008.06463.x;
RA   Martin N.G., McAndrew P.C., Eve P.D., Garrett M.D.;
RT   "Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is mediated by
RT   Src family kinases.";
RL   FEBS J. 275:3099-3109(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-537, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-21 AND SER-40, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL (CD178) by
RT   phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF DPYSL2.
RX   PubMed=19276087; DOI=10.1074/jbc.m807664200;
RA   Varrin-Doyer M., Vincent P., Cavagna S., Auvergnon N., Noraz N.,
RA   Rogemond V., Honnorat J., Moradi-Ameli M., Giraudon P.;
RT   "Phosphorylation of collapsin response mediator protein 2 on Tyr-479
RT   regulates CXCL12-induced T lymphocyte migration.";
RL   J. Biol. Chem. 284:13265-13276(2009).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19258394; DOI=10.1242/jcs.034843;
RA   Sato I., Obata Y., Kasahara K., Nakayama Y., Fukumoto Y., Yamasaki T.,
RA   Yokoyama K.K., Saito T., Yamaguchi N.;
RT   "Differential trafficking of Src, Lyn, Yes and Fyn is specified by the
RT   state of palmitoylation in the SH4 domain.";
RL   J. Cell Sci. 122:965-975(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-336; TYR-345 AND TYR-537, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [19]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21566460; DOI=10.4161/cc.10.9.15495;
RA   Jung J., Lee M.K., Jin Y., Fu S.B., Rosales J.L., Lee K.Y.;
RT   "Clues for c-Yes involvement in the cell cycle and cytokinesis.";
RL   Cell Cycle 10:1502-1503(2011).
RN   [20]
RP   FUNCTION.
RX   PubMed=21713032; DOI=10.1371/journal.pbio.1001090;
RA   Tauzin S., Chaigne-Delalande B., Selva E., Khadra N., Daburon S.,
RA   Contin-Bordes C., Blanco P., Le Seyec J., Ducret T., Counillon L.,
RA   Moreau J.F., Hofman P., Vacher P., Legembre P.;
RT   "The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell
RT   migration pathway.";
RL   PLoS Biol. 9:E1001090-E1001090(2011).
RN   [21]
RP   INTERACTION WITH IL6ST.
RX   PubMed=25731159; DOI=10.1038/nature14228;
RA   Taniguchi K., Wu L.W., Grivennikov S.I., de Jong P.R., Lian I., Yu F.X.,
RA   Wang K., Ho S.B., Boland B.S., Chang J.T., Sandborn W.J., Hardiman G.,
RA   Raz E., Maehara Y., Yoshimura A., Zucman-Rossi J., Guan K.L., Karin M.;
RT   "A gp130-Src-YAP module links inflammation to epithelial regeneration.";
RL   Nature 519:57-62(2015).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 91-152.
RX   PubMed=17418139; DOI=10.1016/j.febslet.2007.03.059;
RA   Martin-Garcia J.M., Luque I., Mateo P.L., Ruiz-Sanz J., Camara-Artigas A.;
RT   "Crystallographic structure of the SH3 domain of the human c-Yes tyrosine
RT   kinase: loop flexibility and amyloid aggregation.";
RL   FEBS Lett. 581:1701-1706(2007).
RN   [23]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-198 AND ARG-282.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor protein tyrosine kinase that is involved in the
CC       regulation of cell growth and survival, apoptosis, cell-cell adhesion,
CC       cytoskeleton remodeling, and differentiation. Stimulation by receptor
CC       tyrosine kinases (RTKs) including EGRF, PDGFR, CSF1R and FGFR leads to
CC       recruitment of YES1 to the phosphorylated receptor, and activation and
CC       phosphorylation of downstream substrates. Upon EGFR activation,
CC       promotes the phosphorylation of PARD3 to favor epithelial tight
CC       junction assembly. Participates in the phosphorylation of specific
CC       junctional components such as CTNND1 by stimulating the FYN and FER
CC       tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by
CC       CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and
CC       induces T-cell migration. Participates in CD95L/FASLG signaling pathway
CC       and mediates AKT-mediated cell migration. Plays a role in cell cycle
CC       progression by phosphorylating the cyclin-dependent kinase 4/CDK4 thus
CC       regulating the G1 phase. Also involved in G2/M progression and
CC       cytokinesis. {ECO:0000269|PubMed:11901164, ECO:0000269|PubMed:18479465,
CC       ECO:0000269|PubMed:19276087, ECO:0000269|PubMed:21566460,
CC       ECO:0000269|PubMed:21713032}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Interacts with YAP1 and CSF1R (By similarity). Interacts with
CC       CTNND1; this interaction allows YES1-mediated activation of FYN and FER
CC       and subsequent phosphorylation of CTNND1 (By similarity). Interacts
CC       with FASLG. Interacts with IL6ST/gp130 (PubMed:25731159). {ECO:0000250,
CC       ECO:0000269|PubMed:19807924, ECO:0000269|PubMed:25731159}.
CC   -!- INTERACTION:
CC       P07947; O14672: ADAM10; NbExp=2; IntAct=EBI-515331, EBI-1536151;
CC       P07947; P09917: ALOX5; NbExp=2; IntAct=EBI-515331, EBI-79934;
CC       P07947; Q9Y2J4: AMOTL2; NbExp=3; IntAct=EBI-515331, EBI-746752;
CC       P07947; P10275: AR; NbExp=5; IntAct=EBI-515331, EBI-608057;
CC       P07947; Q12774: ARHGEF5; NbExp=3; IntAct=EBI-515331, EBI-602199;
CC       P07947; Q9ULH1: ASAP1; NbExp=2; IntAct=EBI-515331, EBI-346622;
CC       P07947; P56945: BCAR1; NbExp=4; IntAct=EBI-515331, EBI-702093;
CC       P07947; Q8TD16-2: BICD2; NbExp=3; IntAct=EBI-515331, EBI-11975051;
CC       P07947; Q6P1W5: C1orf94; NbExp=3; IntAct=EBI-515331, EBI-946029;
CC       P07947; Q9H257-2: CARD9; NbExp=3; IntAct=EBI-515331, EBI-11530605;
CC       P07947; Q13191: CBLB; NbExp=3; IntAct=EBI-515331, EBI-744027;
CC       P07947; Q9ULV8: CBLC; NbExp=3; IntAct=EBI-515331, EBI-2341018;
CC       P07947; Q16543: CDC37; NbExp=4; IntAct=EBI-515331, EBI-295634;
CC       P07947; Q9H5V8: CDCP1; NbExp=2; IntAct=EBI-515331, EBI-1019736;
CC       P07947; Q8IYX8: CEP57L1; NbExp=3; IntAct=EBI-515331, EBI-1104570;
CC       P07947; Q9Y592-2: CEP83; NbExp=3; IntAct=EBI-515331, EBI-11123098;
CC       P07947; Q9HD42: CHMP1A; NbExp=3; IntAct=EBI-515331, EBI-1057156;
CC       P07947; Q16630-2: CPSF6; NbExp=3; IntAct=EBI-515331, EBI-11088043;
CC       P07947; P46109: CRKL; NbExp=3; IntAct=EBI-515331, EBI-910;
CC       P07947; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-515331, EBI-3867333;
CC       P07947; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-515331, EBI-742054;
CC       P07947; Q68D51-2: DENND2C; NbExp=3; IntAct=EBI-515331, EBI-13075846;
CC       P07947; P17661: DES; NbExp=3; IntAct=EBI-515331, EBI-1055572;
CC       P07947; O60496: DOK2; NbExp=3; IntAct=EBI-515331, EBI-1046024;
CC       P07947; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-515331, EBI-2340258;
CC       P07947; O43281-2: EFS; NbExp=5; IntAct=EBI-515331, EBI-11525448;
CC       P07947; P00533: EGFR; NbExp=3; IntAct=EBI-515331, EBI-297353;
CC       P07947; P25445-1: FAS; NbExp=2; IntAct=EBI-515331, EBI-15749113;
CC       P07947; Q96Q35-2: FLACC1; NbExp=3; IntAct=EBI-515331, EBI-11533409;
CC       P07947; Q8IVP5: FUNDC1; NbExp=4; IntAct=EBI-515331, EBI-3059266;
CC       P07947; P51114-2: FXR1; NbExp=3; IntAct=EBI-515331, EBI-11022345;
CC       P07947; P51116: FXR2; NbExp=6; IntAct=EBI-515331, EBI-740459;
CC       P07947; Q13480: GAB1; NbExp=7; IntAct=EBI-515331, EBI-517684;
CC       P07947; O95995: GAS8; NbExp=3; IntAct=EBI-515331, EBI-1052570;
CC       P07947; P14136: GFAP; NbExp=3; IntAct=EBI-515331, EBI-744302;
CC       P07947; P08238: HSP90AB1; NbExp=3; IntAct=EBI-515331, EBI-352572;
CC       P07947; Q9UKT9: IKZF3; NbExp=5; IntAct=EBI-515331, EBI-747204;
CC       P07947; Q96N16: JAKMIP1; NbExp=3; IntAct=EBI-515331, EBI-2680803;
CC       P07947; P10721: KIT; NbExp=7; IntAct=EBI-515331, EBI-1379503;
CC       P07947; Q14847-2: LASP1; NbExp=3; IntAct=EBI-515331, EBI-9088686;
CC       P07947; Q9NUP9: LIN7C; NbExp=3; IntAct=EBI-515331, EBI-1171517;
CC       P07947; Q9H204: MED28; NbExp=2; IntAct=EBI-515331, EBI-514199;
CC       P07947; P08581: MET; NbExp=3; IntAct=EBI-515331, EBI-1039152;
CC       P07947; Q9GZT8: NIF3L1; NbExp=3; IntAct=EBI-515331, EBI-740897;
CC       P07947; Q8TAK6: OLIG1; NbExp=3; IntAct=EBI-515331, EBI-3867416;
CC       P07947; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-515331, EBI-79165;
CC       P07947; Q92569: PIK3R3; NbExp=3; IntAct=EBI-515331, EBI-79893;
CC       P07947; Q9BXM0: PRX; NbExp=4; IntAct=EBI-515331, EBI-1753064;
CC       P07947; I6L996: PTK2; NbExp=6; IntAct=EBI-515331, EBI-10181089;
CC       P07947; Q05397: PTK2; NbExp=2; IntAct=EBI-515331, EBI-702142;
CC       P07947; P49023-2: PXN; NbExp=3; IntAct=EBI-515331, EBI-11954250;
CC       P07947; Q15428: SF3A2; NbExp=3; IntAct=EBI-515331, EBI-2462271;
CC       P07947; Q9NR46: SH3GLB2; NbExp=3; IntAct=EBI-515331, EBI-749607;
CC       P07947; O14508: SOCS2; NbExp=3; IntAct=EBI-515331, EBI-617737;
CC       P07947; O14543: SOCS3; NbExp=6; IntAct=EBI-515331, EBI-714146;
CC       P07947; O14512: SOCS7; NbExp=3; IntAct=EBI-515331, EBI-1539606;
CC       P07947; Q9BWW4: SSBP3; NbExp=6; IntAct=EBI-515331, EBI-2902395;
CC       P07947; Q9UGK3: STAP2; NbExp=3; IntAct=EBI-515331, EBI-1553984;
CC       P07947; Q9NVV9: THAP1; NbExp=6; IntAct=EBI-515331, EBI-741515;
CC       P07947; Q12933: TRAF2; NbExp=6; IntAct=EBI-515331, EBI-355744;
CC       P07947; Q9Y4K3: TRAF6; NbExp=6; IntAct=EBI-515331, EBI-359276;
CC       P07947; Q9C035-3: TRIM5; NbExp=3; IntAct=EBI-515331, EBI-12840050;
CC       P07947; Q3SY00: TSGA10IP; NbExp=3; IntAct=EBI-515331, EBI-10241197;
CC       P07947; Q96BR9: ZBTB8A; NbExp=6; IntAct=EBI-515331, EBI-742740;
CC       P07947; Q96GY0: ZC2HC1A; NbExp=3; IntAct=EBI-515331, EBI-5458880;
CC       P07947; Q7Z4V0: ZNF438; NbExp=3; IntAct=EBI-515331, EBI-11962468;
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome. Cytoplasm, cytosol.
CC       Note=Newly synthesized protein initially accumulates in the Golgi
CC       region and traffics to the plasma membrane through the exocytic
CC       pathway.
CC   -!- TISSUE SPECIFICITY: Expressed in the epithelial cells of renal proximal
CC       tubules and stomach as well as hematopoietic cells in the bone marrow
CC       and spleen in the fetal tissues. In adult, expressed in epithelial
CC       cells of the renal proximal tubules and present in keratinocytes in the
CC       basal epidermal layer of epidermis. {ECO:0000269|PubMed:2021534,
CC       ECO:0000269|PubMed:2067846}.
CC   -!- PTM: Phosphorylation by CSK on the C-terminal tail maintains the enzyme
CC       in an inactive state. Autophosphorylation at Tyr-426 maintains enzyme
CC       activity by blocking CSK-mediated inhibition.
CC       {ECO:0000269|PubMed:11901164, ECO:0000269|PubMed:9281320,
CC       ECO:0000269|PubMed:9794236}.
CC   -!- PTM: Palmitoylation at Cys-3 promotes membrane localization.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M15990; AAA35735.1; -; mRNA.
DR   EMBL; AP001178; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471113; EAX01709.1; -; Genomic_DNA.
DR   EMBL; CH471113; EAX01710.1; -; Genomic_DNA.
DR   EMBL; BC048960; AAH48960.1; -; mRNA.
DR   CCDS; CCDS11824.1; -.
DR   PIR; A26714; TVHUYS.
DR   RefSeq; NP_005424.1; NM_005433.3.
DR   RefSeq; XP_016881449.1; XM_017025960.1.
DR   PDB; 2HDA; X-ray; 1.90 A; A=91-152.
DR   PDBsum; 2HDA; -.
DR   AlphaFoldDB; P07947; -.
DR   SMR; P07947; -.
DR   BioGRID; 113357; 387.
DR   CORUM; P07947; -.
DR   DIP; DIP-33849N; -.
DR   ELM; P07947; -.
DR   IntAct; P07947; 258.
DR   MINT; P07947; -.
DR   STRING; 9606.ENSP00000462468; -.
DR   BindingDB; P07947; -.
DR   ChEMBL; CHEMBL2073; -.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P07947; -.
DR   GuidetoPHARMACOLOGY; 2284; -.
DR   GlyGen; P07947; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P07947; -.
DR   PhosphoSitePlus; P07947; -.
DR   SwissPalm; P07947; -.
DR   BioMuta; YES1; -.
DR   DMDM; 125870; -.
DR   EPD; P07947; -.
DR   jPOST; P07947; -.
DR   MassIVE; P07947; -.
DR   MaxQB; P07947; -.
DR   PaxDb; P07947; -.
DR   PeptideAtlas; P07947; -.
DR   PRIDE; P07947; -.
DR   ProteomicsDB; 52044; -.
DR   Antibodypedia; 3819; 504 antibodies from 36 providers.
DR   DNASU; 7525; -.
DR   Ensembl; ENST00000314574.5; ENSP00000324740.4; ENSG00000176105.14.
DR   Ensembl; ENST00000584307.5; ENSP00000462468.1; ENSG00000176105.14.
DR   GeneID; 7525; -.
DR   KEGG; hsa:7525; -.
DR   MANE-Select; ENST00000314574.5; ENSP00000324740.4; NM_005433.4; NP_005424.1.
DR   UCSC; uc002kky.4; human.
DR   CTD; 7525; -.
DR   DisGeNET; 7525; -.
DR   GeneCards; YES1; -.
DR   HGNC; HGNC:12841; YES1.
DR   HPA; ENSG00000176105; Low tissue specificity.
DR   MIM; 164880; gene.
DR   neXtProt; NX_P07947; -.
DR   OpenTargets; ENSG00000176105; -.
DR   PharmGKB; PA37432; -.
DR   VEuPathDB; HostDB:ENSG00000176105; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   GeneTree; ENSGT00940000154920; -.
DR   HOGENOM; CLU_000288_7_2_1; -.
DR   InParanoid; P07947; -.
DR   OrthoDB; 539311at2759; -.
DR   PhylomeDB; P07947; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P07947; -.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-389356; CD28 co-stimulation.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   Reactome; R-HSA-8940973; RUNX2 regulates osteoblast differentiation.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants.
DR   SignaLink; P07947; -.
DR   SIGNOR; P07947; -.
DR   BioGRID-ORCS; 7525; 23 hits in 1108 CRISPR screens.
DR   ChiTaRS; YES1; human.
DR   EvolutionaryTrace; P07947; -.
DR   GeneWiki; YES1; -.
DR   GenomeRNAi; 7525; -.
DR   Pharos; P07947; Tclin.
DR   PRO; PR:P07947; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; P07947; protein.
DR   Bgee; ENSG00000176105; Expressed in secondary oocyte and 215 other tissues.
DR   ExpressionAtlas; P07947; baseline and differential.
DR   Genevisible; P07947; HS.
DR   GO; GO:0005884; C:actin filament; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IPI:CAFA.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0044325; F:transmembrane transporter binding; IPI:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0036211; P:protein modification process; TAS:ProtInc.
DR   GO; GO:0010827; P:regulation of glucose transmembrane transport; IEA:Ensembl.
DR   GO; GO:0043114; P:regulation of vascular permeability; TAS:BHF-UCL.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd12007; SH3_Yes; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR035751; Yes_SH3.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Cytoplasm; Cytoskeleton; Kinase;
KW   Lipoprotein; Membrane; Myristate; Nucleotide-binding; Palmitate;
KW   Phosphoprotein; Proto-oncogene; Reference proteome; SH2 domain; SH3 domain;
KW   Transferase; Tyrosine-protein kinase.
FT   INIT_MET        1
FT                   /note="Removed"
FT   CHAIN           2..543
FT                   /note="Tyrosine-protein kinase Yes"
FT                   /id="PRO_0000088181"
FT   DOMAIN          91..152
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          158..255
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          277..530
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..45
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        21..45
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        396
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         283..291
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         305
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         21
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         32
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q04736"
FT   MOD_RES         40
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         336
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         345
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         426
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:9794236"
FT   MOD_RES         446
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         537
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000250"
FT   LIPID           3
FT                   /note="S-palmitoyl cysteine; in membrane form"
FT                   /evidence="ECO:0000250"
FT   VARIANT         198
FT                   /note="I -> V (in dbSNP:rs34580680)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041879"
FT   VARIANT         282
FT                   /note="K -> R (in dbSNP:rs35126906)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041880"
FT   MUTAGEN         426
FT                   /note="Y->F: About 50% loss of CSK-mediated inhibition."
FT                   /evidence="ECO:0000269|PubMed:9794236"
FT   STRAND          93..100
FT                   /evidence="ECO:0007829|PDB:2HDA"
FT   STRAND          117..121
FT                   /evidence="ECO:0007829|PDB:2HDA"
FT   STRAND          126..133
FT                   /evidence="ECO:0007829|PDB:2HDA"
FT   TURN            134..136
FT                   /evidence="ECO:0007829|PDB:2HDA"
FT   STRAND          139..143
FT                   /evidence="ECO:0007829|PDB:2HDA"
FT   HELIX           144..146
FT                   /evidence="ECO:0007829|PDB:2HDA"
FT   STRAND          147..149
FT                   /evidence="ECO:0007829|PDB:2HDA"
SQ   SEQUENCE   543 AA;  60801 MW;  A2B376084686BBCD CRC64;
     MGCIKSKENK SPAIKYRPEN TPEPVSTSVS HYGAEPTTVS PCPSSSAKGT AVNFSSLSMT
     PFGGSSGVTP FGGASSSFSV VPSSYPAGLT GGVTIFVALY DYEARTTEDL SFKKGERFQI
     INNTEGDWWE ARSIATGKNG YIPSNYVAPA DSIQAEEWYF GKMGRKDAER LLLNPGNQRG
     IFLVRESETT KGAYSLSIRD WDEIRGDNVK HYKIRKLDNG GYYITTRAQF DTLQKLVKHY
     TEHADGLCHK LTTVCPTVKP QTQGLAKDAW EIPRESLRLE VKLGQGCFGE VWMGTWNGTT
     KVAIKTLKPG TMMPEAFLQE AQIMKKLRHD KLVPLYAVVS EEPIYIVTEF MSKGSLLDFL
     KEGDGKYLKL PQLVDMAAQI ADGMAYIERM NYIHRDLRAA NILVGENLVC KIADFGLARL
     IEDNEYTARQ GAKFPIKWTA PEAALYGRFT IKSDVWSFGI LQTELVTKGR VPYPGMVNRE
     VLEQVERGYR MPCPQGCPES LHELMNLCWK KDPDERPTFE YIQSFLEDYF TATEPQYQPG
     ENL
//
